David Lavie

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat et al. · New England Journal of Medicine · 2020 · 2.6K citations · Full text

Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin.

Daniel Meruelo, G. Lavie, David Lavie · Proceedings of the National Academy of Sciences · 1988 · 427 citations · Full text

Immunology, Antimicrobial Chemotherapy, Antiviral Drug +19

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

Claire Harrison, Alessandro M. Vannucchi, Uwe Platzbecker et al. · The Lancet Haematology · 2017 · 301 citations

Hematological Malignancy, Momelotinib Versus, Simplify 2 +5

Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin.

G. Lavie, Fred Valentine, Brandi Levin et al. · Proceedings of the National Academy of Sciences · 1989 · 208 citations · Full text

Electron Microscopy, Neurovirology, Medicine +15

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 164 citations

Hematological Malignancy, Bone Marrow Failure, Momelotinib Versus Danazol +6